Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 53
Confirmed by 3 outlets

FDA Rejects Summit's Ivonescimab Lung Cancer Filing Over Survival Data

Summit Therapeutics says the FDA handed back its ivonescimab application for previously treated lung cancer, and the overall-survival numbers are the reason. The Phase III HARMONi trial hit its progression-free survival goal but missed statistical significance on overall survival.

By the Paparazzi desk November 15, 2026 · 10:03 AM · Sources: 3 outlets · 1 view
Fact boxTrust 66/100 · Developing
What we verified
  • 3 sources report it: casrai.org, morningstar.com, hoodline.com.
  • The source published it on Nov 15, 2026 at 10:03 AM.
What we couldn't

Nothing open. Every check passed.

Summit Therapeutics said on November 15, 2026 that the US Food and Drug Administration issued a complete response letter for its ivonescimab application in previously treated lung cancer. In the company's statement, carried by Business Wire, the filing cannot be approved as it stands because the overall-survival evidence did not clear the agency's bar. Reuters and BioSpace both reported the decision the same day.

The application sought approval for ivonescimab paired with platinum-containing chemotherapy in locally advanced or metastatic non-small cell lung cancer, for patients who had already received an EGFR tyrosine kinase inhibitor. The data came from HARMONi, a global, randomized, double-blind Phase III study with two primary endpoints: progression-free survival and overall survival.

Sponsored

Summit reported that HARMONi met its progression-free survival endpoint, but the primary overall-survival analysis came in without statistical significance. According to the company, the FDA viewed that progression-free survival win as not enough to establish a positive benefit-risk profile on its own.

The FDA describes a complete response letter as what it sends when an application cannot be approved in its current form; the letter lays out the deficiencies found in review and may suggest steps toward marketing approval. Summit said it plans to keep pushing its broader ivonescimab development program.

Price since story
RKLB-3.88%
Market data, not advice.

TopicsSummit Therapeutics · FDA · ivonescimab · HARMONi · EGFR · Reuters · BioSpace · Business Wire

Share

Written by AI from verified reporting. Not financial advice.

More stories

  • Health & science 53 minutes ago · finance.yahoo.com · 0 views
    Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
  • Health & science 3 hours ago · casrai.org · 0 views
    FDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
  • Health & science 4 hours ago · nbcnews.com · Caught by @nina.anggraini29 · 0 views
    Measles Is Endemic Again as the U.S. Loses Its Elimination Status
  • Health & science 4 hours ago · aol.com · 1 view
    FDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.